File(s) not publicly available
Neuropeptide Y Leu7Pro polymorphism associated with the metabolic syndrome and its features in patients with coronary artery disease
journal contribution
posted on 2023-06-08, 13:46 authored by Ali Masoudi Kazemabad, Khadijeh Jamialahmadi, Mohsen Moohebati, Majid Mojarrad, Raheleh Dehghan Manshadi, Saeed Akhlaghi, Gordon FernsGordon Ferns, Majid Ghayour-MobarhanThe metabolic syndrome (MetS) is characterized by constellation of clinical and biochemical features that increase the risk of cardiovascular disease. Neuropeptide Y (NPY) is a neurotransmitter and enhances the development of obesity and other aspects of MetS. We determined the association between NPY Leu7Pro polymorphism and features of MetS in Iranian patients with coronary artery disease (CAD). A total of 550 patients with CAD including individuals with (n = 184) and without MetS (n = 366) were genotyped by polymerase chain reaction-restriction fragment length polymorphism. A significantly higher frequency of the Leu7Pro polymorphism was found in patients with MetS compared with the non-MetS patients (P = .001). Furthermore, there was a significant difference in Pro7 frequency between diabetics versus nondiabetics (P = .005), dyslipidemic versus nondyslipidemic (P = .04), and obese versus nonobese (P = .001) in this population. Leu7Pro polymorphism is associated with the MetS in patients with CAD.
History
Publication status
- Published
Journal
AngiologyISSN
1940-1574Publisher
Sage JournalsExternal DOI
Issue
1Volume
64Page range
40-45Department affiliated with
- Division of Medical Education Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-11-16Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC